Page 5 - Optimizerx Corp News Today

Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.

“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

Physicians would make a different therapy choice for 33% of patients if medication access was not a factor, and physicians had to change their treatment plan

OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the rapid growth from the convergence of technology and healthcare...

Analysts forecast that OptimizeRx Co. (NASDAQ:OPRX – Get Rating) will report earnings of $0.19 per share for the current quarter, Zacks reports. Three analysts have made estimates for OptimizeRx’s earnings. The lowest EPS estimate is $0.18 and the highest is $0.19. OptimizeRx reported earnings per share of $0.03 in the same quarter last year, which […]

OptimizeRx Co. (NASDAQ:OPRX – Get Rating) – Equities research analysts at William Blair raised their Q3 2023 earnings estimates for shares of OptimizeRx in a research report issued on Tuesday, March 29th. William Blair analyst R. Daniels now forecasts that the company will earn $0.20 per share for the quarter, up from their prior forecast […]

OptimizeRx Co. (NASDAQ:OPRX – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $41.37, but opened at $40.20. OptimizeRx shares last traded at $40.05, with a volume of 835 shares traded. Several research firms have weighed in on OPRX. TheStreet lowered shares of OptimizeRx from a “b-” […]

Precision Wealth Strategies LLC increased its stake in OptimizeRx Co. (NASDAQ:OPRX – Get Rating) by 61.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,929 shares of the company’s stock after acquiring an additional 3,783 shares during the quarter. Precision Wealth Strategies LLC owned […]

Wall Street brokerages predict that OptimizeRx Co. (NASDAQ:OPRX – Get Rating) will report $14.92 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for OptimizeRx’s earnings, with the highest sales estimate coming in at $15.19 million and the lowest estimate coming in at $14.60 million. OptimizeRx reported […]

Bearish Bets: 2 Small-Cap Stocks You Should Consider Shorting This Week...SSTI